Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Pay Motorola $5M in Settlement Of Microarray Patent Infringement Litigation


Nanogen and Motorola have settled their patent infringement dispute, with Nanogen agreeing to pay Motorola $5 million in cash and stock for a license to two claims of the patent at issue.

This settlement removes a potential obstacle in the way of both companies’ commercializing their somewhat similar electricity-based DNA detection systems for diagnostics. Motorola is in the process of bringing its eSensor Platform, which uses label-free bioelectric detection, to the market as a lab-based diagnostic test, while Nanogen, under its new CEO Randy White, has recently plunged into the diagnostics arena with its programmable electrode probe arrays.

While the settlement could also be seen as a setback for Nanogen and a break for Motorola in this neck-and-neck DNA diagnostics race, Nanogen is well funded enough, with $87.3 million in cash and short-term investments at the end of the first quarter, to swallow the payment without being thrown off course.

“By coming to a settlement, both companies also avoid further legal costs,’ said White in a statement. “We are pleased to put the action behind us and we will continue to commercialize the NanoChip Molecular Biology Workstation in the clinical research market and to develop it for potential use in the clinical diagnostics market.’

Nanogen originally filed a declaratory judgment against Motorola, Genometrix, and MIT in April 2000 alleging the invalidity of patent Number 5,653,939, entitled “Optical and electrical methods and apparatus for molecular detection. The patent was initially assigned to MIT in 1993, and then licensed to Beckman Coulter and Genometrix, the latter of which sublicensed the patent to Motorola.

A month after this action, Motorola filed a counterclaim, alleging infringement of the patent. The same month, Beckman Coulter granted Nanogen a license to the patent.

In the settlement, Nanogen is licensing claims 16 and 39 of this patent from Motorola. The company is also dropping its declaratory judgment against Genometrix, which closed its doors in June, and MIT.


The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.